Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2022—OGT launched its SureSeq Myeloid Plus panel designed to detect a range of aberrations, including single nucleotide variations, insertions/deletions, internal tandem duplications, and partial tandem duplications in 49 genes implicated in myeloid disorders such as acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome.
December 2022—Primera Technology showcased its Signature EVO slide and cassette printers at the National Society for Histotechnology convention.
December 2022—Roche announced plans for the U.S. launch of the Cobas 5800 system, a compact, fully-automated molecular instrument that aims to offer a flexible PCR testing solution to help clinicians diagnose infectious diseases.
December 2022—Verichem Laboratories announced the availability of a six-level, protein-based kit designed for the calibration or calibration verification of lactate assays on automated clinical systems. The liquid-stable, ready-to-use product contains concentration levels of lactate ranging from 3.2 mg/dL to 160 mg/dL. The format is free of glycols, surfactants, azides, and other interfering substances. Shelf life is 18 months from the manufacturing date.
November 2022—Bio-Rad Laboratories has collaborated with Beckman Coulter to offer InteliQ load-and-go quality controls for use on Beckman Coulter DxC AU and AU series clinical chemistry analyzers.
November 2022—Siemens Healthineers announced that its Innovance VWF Ac assay is available to U.S. laboratories for use on the company’s BCS XP system and on Sysmex CS-2500 and CS-5100 hemostasis analyzers.
November 2022—Roche announced that the FDA has granted 510(k) clearance for the Cobas SARS-CoV-2 Qualitative PCR test for use on the automated Cobas 6800 and Cobas 8800 systems. It is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal and nasopharyngeal swab specimens collected from symptomatic patients who are suspected of having COVID-19 by their health care provider. The single-well, dual-target assay includes specific detection of SARS-CoV-2 and pan-sarbecovirus detection for the sarbecovirus subgenus that includes SARS-CoV-2.
November 2022—Traceable announced it has updated four of its products—a refrigerator/freezer digital thermometer with probe, a thermohygrometer with clock, a three-channel timer with alarm, and a four-channel timer with clock—to be more user friendly, economical, and higher performing. The updates are based on feedback that the company gathered from customer focus groups and industry conversations to learn how clinics, laboratories, academic institutions, logistics companies, and other organizations use its products.
November 2022—Verichem Laboratories announced the availability of a ready-to-use set of multilevel clinical reference materials for the calibration and calibration verification of ethanol assays on a range of diagnostic testing systems. The protein-based liquid standards are free of surfactants, glycols, azides, and other interfering substances. Each kit contains 5 mL of material per vial at the six available concentration levels and has a shelf life of 18 months when stored at 2° to 8°C. The product also contains a known linear relation for acetaminophen, lactate, and salicylate.
November 2022—Thermo Fisher Scientific announced it has entered into a definitive agreement to acquire the Binding Site Group from a shareholder group led by European private equity firm Nordic Capital. The all-cash transaction is valued at approximately $2.6 billion at current exchange rates, Thermo Fisher reported in a press release.
